Haemostasis and Thrombosis Task Force for the British Committee for Standards in Haematology (May 1998). "Guidelines on oral anticoagulation: 3rd edition". Br J Haematol. 101 (2): 374–387. doi:10.1046/j.1365-2141.1998.00715.x. PMID9609538.
Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM (November 2004). "Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis". The Medical Journal of Australia. 181 (9): 492–7. doi:10.5694/j.1326-5377.2004.tb06407.x. PMID15516194. S2CID3035209.
Irizarry-Gatell VM, Bacchus MW, De Leo EK, Zhang Y, Lagasse CA, Khanna AY, et al. (April 2024). "The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage". Blood Coagul Fibrinolysis. 35 (3): 94–100. doi:10.1097/MBC.0000000000001279. PMID38358898.
"Factor IX (Recombinant)". The American Society of Health-System Pharmacists. Archived from the original on 24 September 2017. Retrieved 8 December 2016.
europa.eu
ema.europa.eu
"Active substance: human prothrombin complex"(PDF). List of nationally authorised medicinal products. European Medicines Agency. January 2017. EMA/45481/2017, PSUSA/00001638/201604.
World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06.
World Health Organization (2015). The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Vol. 994. Geneva: World Health Organization. p. 510. hdl:10665/189763. ISBN978-92-4-120994-6. ISSN0512-3054. WHO technical report series.
Haemostasis and Thrombosis Task Force for the British Committee for Standards in Haematology (May 1998). "Guidelines on oral anticoagulation: 3rd edition". Br J Haematol. 101 (2): 374–387. doi:10.1046/j.1365-2141.1998.00715.x. PMID9609538.
Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM (November 2004). "Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis". The Medical Journal of Australia. 181 (9): 492–7. doi:10.5694/j.1326-5377.2004.tb06407.x. PMID15516194. S2CID3035209.
Irizarry-Gatell VM, Bacchus MW, De Leo EK, Zhang Y, Lagasse CA, Khanna AY, et al. (April 2024). "The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage". Blood Coagul Fibrinolysis. 35 (3): 94–100. doi:10.1097/MBC.0000000000001279. PMID38358898.
Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM (November 2004). "Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis". The Medical Journal of Australia. 181 (9): 492–7. doi:10.5694/j.1326-5377.2004.tb06407.x. PMID15516194. S2CID3035209.
"Factor IX (Recombinant)". The American Society of Health-System Pharmacists. Archived from the original on 24 September 2017. Retrieved 8 December 2016.
World Health Organization (2015). The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Vol. 994. Geneva: World Health Organization. p. 510. hdl:10665/189763. ISBN978-92-4-120994-6. ISSN0512-3054. WHO technical report series.